Eckert & Ziegler SE (CHIX:EUZD) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:EUZD Eckert & Ziegler SE CHIX:EUZD
95 GF Score
Price €15.19
GF Value €16.39
Valuation Fairly Valued
View Full Analysis

What is Eckert & Ziegler SE FFO per Share?

FFO per Share only applies to REITs.

CHIX:EUZD
95GF Score
Eckert & Ziegler SE CHIX:EUZD
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Eckert & Ziegler SE (CHIX:EUZD) Overvalued in 2026?

Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued. The current stock price of €15.19 is trading 7.3% below its estimated GF Value™ of €16.39. GuruFocus considers Eckert & Ziegler SE to be Fairly Valued.

Key valuation signals for CHIX:EUZD:

  • FFO per Share:
  • GF Value™: €16.39 vs. price of €15.19 (7.3% below fair value)
  • GF Score™: 95/100

No single metric tells the full story. See the CHIX:EUZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eckert & Ziegler SE Business Description

Address Robert-Rossle-Street 10, Berlin, BB, DEU, 13125
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
95GF Score

Get the complete analysis for CHIX:EUZD

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.19
Price
€16.39
GF Value